Already FDA-approved to treat major depression and migraines, TMS can now be marketed as a treatment for obsessive compulsive disorder Santa Barbara, Calif., September 21, 2018 – Transcranial Magnetic Stimulation (TMS) therapy is rapidly growing in popularity as a treatment [..]
We are pleased to announce the adoption and implementation of a new Transcranial Magnetic Stimulation Local Coverage Determination (LCD) with National Government Services ( NGS) effective August 15, 2014. This coverage decision will now provide access to TMS for approximately 9.3 Million members in NY, CT, ME, NH, VT, RI, MA, IL, WI, MN. View article here.
Policy Link: The coverage medical policy is publicly available via the website: This is the link for the Connecticut LCD but it is the same for all states in the two Jurisdictions.